VJHemOnc is committed to improving our service to you

MDS 2020 | Novel drug targets for MDS

VJHemOnc is committed to improving our service to you

Stephen Nimer

Stephen Nimer, MD, Sylvester Comprehensive Cancer Center and University of Miami, Miami, FL, discusses some of the drug targets for novel treatment options. Specifically, he mentions the potential of using APR246, venetoclax or luspatercept in combination with hypomethylating agents (HMA). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter